In recent years, a series of adverse chain reactions of malignant tumor progression due to EZH2 overexpression were reported more frequently, including malignant tumors like HCC [11], gastric cancer [12], breast cancer [13], esophageal cancer [14] and endometrial carcinoma [15]. This evidence concerns the gene EZH2 and hepatocellular carcinoma.